Description: Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Home Page: www.saniona.com
Smedeland 26B
Glostrup,
2600
Denmark
Phone:
45 70 70 52 25
Officers
| Name | Title |
|---|---|
| Mr. Jorgen Drejer Ph.D. | Founder, Chairman & Deputy CEO |
| Mr. Rami Levin | Pres |
| Mr. Thomas Feldthus M.Sc., MBA | Co-Founder & CEO |
| Ms. Anita Milland B.Com. | Chief Financial Officer |
| Mr. Karin Sandager Nielsen Ph.D. | Chief Scientific Officer |
| Mr. Palle Christophersen M.S., Ph.D. | Exec. VP of Research |
| Mr. Janus Schreiber Larsen | Chief Devel. Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.097 |
| Price-to-Sales TTM: | 12.5544 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 25 |